Document is current
Any future updates will be listed below
-
Authors
Kumar, Shania https://orcid.org/0009-0000-5514-3023
Dalbeth, Nicola https://orcid.org/0000-0003-4632-4476
Gasteiger, Chiara https://orcid.org/0000-0002-0597-2349
-
Funding
Funding for this research was provided by:
Arthritis New Zealand
University of Auckland
- License Information
-
More Information
Article History
Accepted: 29 January 2026
First Online: 24 February 2026
Declarations
:
: Nicola Dalbeth has received consulting fees, speaker fees, or grants from Novartis, Horizon, Selecta, Arthrosi, LG Chem, JPI, PTC Therapeutics, Protalix, Unlocked Labs, Hikma, Dexcel Pharma, Shanton Pharma, Sobi, Avalo, Biomarin, Crystalys, SK Chemicals, Medcryst, Convergence Bio, Implicit, and GondolaBio outside the submitted work. Funding sources were not involved in the conception or writing of this review. The other authors declare no conflicts of interest.
: This research was funded by an Arthritis NZ Mateponapona Aotearoa research grant as part of their 2024/2025 annual funding round (R332 Gasteiger).
: Data are available on request.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: ND: Conceptualization; methodology; supervision; writing—review and editing. CG: Conceptualization; methodology; supervision; writing—review and editing; visualization. SK: Investigation; data curation; formal analysis; writing—original draft.
